CD47 Knock‐Out Using CRISPR‐Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo
Advanced Science · 2025-03 · 12 (12)
DOI: 10.1002/advs.202407262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 31.01.2025. Verfasst von Nadia Rouatbi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, Lo…. Hauptthemen laut MEDLINE: Glioblastoma, CRISPR-Cas Systems, CD47 Antigen, Nanoparticles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain Tumour Charity, Cancer Research Institute / Wade F.B. Thompson CLIP, Medical Research Council.
Abstract (Originalsprache)
Immune checkpoint (ICP) blockade has shown limited effectiveness in glioblastoma (GBM), particularly in the mesenchymal subtype, where interactions between immune cells and glioblastoma cancer stem cells (GSCs) drive immunosuppression and therapy resistance. Tailoring ICPs specific to GSCs can enhance the antitumor immune response. This study proposes the use of lipid nanoparticles (LNPs) encapsulating CRISPR RNAs as an in vivo screening tool for ICPs in a syngeneic model of mesenchymal GSCs. Using PD‐L1 and CD47 to validate the proof of concept, intratumoral administration of LNPs in orthotopic tumors achieved efficient editing of ICPs, leading to enhanced immune cell infiltration within the tumor microenvironment. Targeting CD47 reduced tumor growth, suggesting improved cancer cell sensitization to the immune system post‐ICP editing. The study positions LNPs as a robust tool for in vivo validation of ICPs as therapeutic targets in clinically relevant GBM models. LNPs could serve as a screening tool in patient‐derived xenografts to identify and optimize ICP combinations, potentially expediting ICP translation and enhancing personalized GBM immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK.
- Comprehensive Cancer Centre, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London, SE1 1UL, UK.
- Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
- Centre for Regenerative Medicine, Institute for Regeneration and Repair & Cancer Research UK Scotland Centre, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU, UK.
ORCID-Profile: Khuloud T Al-Jamal
Förderung
- Brain Tumour Charity
- Cancer Research Institute / Wade F.B. Thompson CLIP
- Medical Research Council
- Wellcome Trust
- Cancer Research UK
- Brain Research UK
Zitieren
APA
Rouatbi, N., Walters, A. A., Zam, A., Lim, Y. M., Marrocu, A., Liam-Or, R., Anstee, J. E., Arnold, J. N., Wang, J. T., Pollard, S. M., & Al-Jamal, K. T. (2025). CD47 Knock‐Out Using CRISPR‐Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo. Advanced Science, 12(12). https://doi.org/10.1002/advs.202407262
Vancouver
Rouatbi N, Walters AA, Zam A, Lim YM, Marrocu A, Liam-Or R, et al. CD47 Knock‐Out Using CRISPR‐Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo. Advanced Science. 2025;12(12). doi:10.1002/advs.202407262
BibTeX
@article{Rouatbi2025,
author = {Rouatbi, Nadia and Walters, Adam A and Zam, Alaa and Lim, Yau Mun and Marrocu, Alessia and Liam-Or, Revadee and Anstee, Joanne E and Arnold, James N and Wang, Julie Tzu-Wen and Pollard, Steven M and Al-Jamal, Khuloud T},
title = {CD47 Knock‐Out Using CRISPR‐Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {12},
doi = {10.1002/advs.202407262}
}
EUVIMED